WuXi XDC Cayman Inc. (L74.F)

2.0200 +0.0700 (+3.59%) As of 09:59AM CEST. Market open.

WuXi XDC Cayman Inc.

No. 11 Xinhui Ring Road
Xinwu District
Wuxi
China

https://wuxixdc.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 1,178

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jincai Li Ph.D.	CEO & Executive Director	371.96k	N/A	1973
Mr. Xiaojie Xi	Company Secretary, CFO & Executive Director	329.99k	N/A	1976
Mr. Jingwei Zhang	COO & Executive Director	249.13k	N/A	1969
Dr. Meiying Zhu	Chief Technology Officer	N/A	N/A	1966
Dr. Jianjun Luo	Vice President	N/A	N/A	1968

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Corporate Governance

WuXi XDC Cayman Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.